A 5‐marker immunohistochemical panel of <scp>CK17</scp> , <scp>MEP1A</scp> , <scp>PAX8</scp> , <scp>SMAD4</scp> , and <scp>CDX2</scp> to distinguish ovarian mucinous carcinoma from metastatic pancreatic ductal adenocarcinoma
This is the first ancillary IHC panel to distinguish between PDAC and OMT with high accuracy. These results inform further studies on diagnostic workflows tailored to the complexity of metastatic presentations of tumours at the ovary.
Authors
- Nicola S. Meagher (ORCID: https://orcid.org/0000-0001-9134-2118)
- Parham Minoo (ORCID: https://orcid.org/0000-0003-1057-0042)
- Kylie L. Gorringe (ORCID: https://orcid.org/0000-0001-5681-2022)
- Astrid De Boeck
- Martin Köbel (ORCID: https://orcid.org/0000-0002-6615-2037)
- Eun Young Kang (ORCID: https://orcid.org/0000-0001-6805-5727)
- Cheng‐Han Lee (ORCID: https://orcid.org/0000-0003-2094-1222)
Institutions
- The University of Sydney (AU)
- New South Wales Department of Health (AU)
- University of Alberta (CA)
- University of Calgary (CA)
- Peter MacCallum Cancer Centre (AU)
- UNSW Sydney (AU)
- Cancer Council NSW (AU)
Publication Details
- Journal
- Histopathology
- Published
- 2025-09-19
- DOI
- https://doi.org/10.1111/his.70002
- Primary Topic
- Ovarian cancer diagnosis and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Ovarian Cancer Research Alliance